Vivanza Biosciences Ltd
Incorporated in 2016, Vivanza Biosciences Ltd is in the business of providing medicines and healthcare solutions[1]
- Market Cap ₹ 7.92 Cr.
- Current Price ₹ 1.98
- High / Low ₹ 4.36 / 1.90
- Stock P/E
- Book Value ₹ 0.99
- Dividend Yield 0.00 %
- ROCE -2.77 %
- ROE -15.6 %
- Face Value ₹ 1.00
Pros
- Company is expected to give good quarter
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -5.02% over past five years.
- Promoter holding is low: 20.0%
- Company has a low return on equity of 3.85% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 398 days.
- Promoter holding has decreased over last 3 years: -27.8%
- Working capital days have increased from 82.8 days to 154 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 3.46 | 6.44 | 2.66 | 9.56 | 9.89 | 10.39 | 17.81 | 27.84 | 7.39 | 13.92 | |
| 0.06 | 3.77 | 5.84 | 2.68 | 9.90 | 9.80 | 10.45 | 17.14 | 26.76 | 7.75 | 14.49 | |
| Operating Profit | -0.06 | -0.31 | 0.60 | -0.02 | -0.34 | 0.09 | -0.06 | 0.67 | 1.08 | -0.36 | -0.57 | 
| OPM % | -8.96% | 9.32% | -0.75% | -3.56% | 0.91% | -0.58% | 3.76% | 3.88% | -4.87% | -4.09% | |
| 0.00 | 0.04 | 0.00 | 0.00 | 0.57 | 0.51 | 0.83 | 0.48 | 0.05 | 0.06 | 0.08 | |
| Interest | 0.00 | 0.04 | 0.37 | 0.42 | 0.44 | 0.47 | 0.43 | 0.43 | 0.42 | 0.35 | 0.34 | 
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 | 
| Profit before tax | -0.06 | -0.31 | 0.23 | -0.44 | -0.21 | 0.12 | 0.33 | 0.72 | 0.70 | -0.66 | -0.83 | 
| Tax % | 0.00% | 0.00% | 13.04% | 0.00% | 0.00% | 41.67% | 0.00% | 16.67% | 21.43% | 1.52% | |
| -0.06 | -0.31 | 0.21 | -0.44 | -0.21 | 0.08 | 0.33 | 0.60 | 0.55 | -0.67 | -0.85 | |
| EPS in Rs | -0.32 | -0.08 | 0.05 | -0.11 | -0.05 | 0.02 | 0.08 | 0.15 | 0.14 | -0.17 | -0.22 | 
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % | 
| 5 Years: | -5% | 
| 3 Years: | -11% | 
| TTM: | -34% | 
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % | 
| 5 Years: | % | 
| 3 Years: | % | 
| TTM: | -358% | 
| Stock Price CAGR | |
|---|---|
| 10 Years: | -8% | 
| 5 Years: | -12% | 
| 3 Years: | -48% | 
| 1 Year: | -47% | 
| Return on Equity | |
|---|---|
| 10 Years: | % | 
| 5 Years: | 5% | 
| 3 Years: | 4% | 
| Last Year: | -16% | 
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.19 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 
| Reserves | -0.16 | -0.47 | -0.27 | -0.71 | -0.92 | -0.84 | -0.51 | 0.09 | 0.64 | -0.04 | 
| 0.50 | 0.90 | 1.32 | 1.48 | 0.39 | 0.36 | 5.51 | 8.00 | 5.17 | 8.65 | |
| 0.11 | 2.73 | 5.10 | 6.33 | 8.89 | 4.93 | 6.56 | 10.39 | 9.69 | 3.85 | |
| Total Liabilities | 0.64 | 7.16 | 10.15 | 11.10 | 12.36 | 8.45 | 15.56 | 22.48 | 19.50 | 16.46 | 
| 0.00 | 2.31 | 2.31 | 2.31 | 2.31 | 2.32 | 2.32 | 2.31 | 2.34 | 2.33 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 
| 0.64 | 4.85 | 7.84 | 8.79 | 10.05 | 6.13 | 13.24 | 20.17 | 17.16 | 14.13 | |
| Total Assets | 0.64 | 7.16 | 10.15 | 11.10 | 12.36 | 8.45 | 15.56 | 22.48 | 19.50 | 16.46 | 
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | -2.07 | -0.09 | 0.86 | 2.98 | -3.08 | 2.47 | -0.95 | 2.04 | -2.50 | |
| 0.00 | 1.90 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | 0.00 | -0.04 | -0.01 | |
| 0.00 | 0.39 | -0.55 | -0.89 | -2.75 | 2.80 | -2.48 | 1.03 | -1.98 | 2.46 | |
| Net Cash Flow | 0.00 | 0.23 | -0.64 | -0.03 | 0.22 | -0.30 | -0.01 | 0.09 | 0.03 | -0.05 | 
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 266.89 | 287.35 | 782.14 | 249.70 | 230.66 | 275.42 | 255.77 | 151.30 | 398.09 | |
| Inventory Days | 215.20 | 150.49 | 309.32 | 38.07 | 25.93 | 91.82 | 54.64 | 28.27 | 120.95 | |
| Days Payable | 304.36 | 319.46 | 878.47 | 319.47 | 153.98 | 207.06 | 211.26 | 115.76 | 140.22 | |
| Cash Conversion Cycle | 177.72 | 118.38 | 212.99 | -31.71 | 102.61 | 160.18 | 99.15 | 63.81 | 378.83 | |
| Working Capital Days | 332.30 | 237.48 | 469.29 | 109.19 | 104.07 | 102.58 | 50.42 | 44.45 | 153.61 | |
| ROCE % | -10.48% | 12.66% | -0.41% | 5.58% | 16.88% | 12.14% | 10.91% | 10.23% | -2.77% | 
Documents
Announcements
- 
        
          Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
          
            6 Oct - Confirmation Certificate under Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018, received from Purva Sharegistry (I) Pvt. Ltd., Registrar and Share Transfer Agent (RTA) …
- 
        
          Announcement under Regulation 30 (LODR)-Change in Directorate
          
            6 Oct - Hitesh R. Rijwani regularised as Independent Director (12/05/2025–11/05/2030); Sarang Pathak appointed Non-Independent Director (30/08/2025–29/08/2030).
- 
        
          Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
          
            5 Oct - 43rd AGM (25 Sep 2025) approved MOA change adding agro, renewable energy, real estate, drones, IT, data centers.
- 
        
          Closure of Trading Window
          
            29 Sep - Trading window closed 01-Oct-2025 until 48 hours after results for quarter ended 30-Sep-2025.
- 
        
          Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
          
            27 Sep - 25 Sep 2025 AGM: FY2025 accounts adopted; director regularizations, MOA altered; secretarial auditor appointed.
Annual reports
- 
    
      Financial Year 2025
      from bse
- 
    
      Financial Year 2024
      from bse
- 
    
      Financial Year 2023
      from bse
- 
    
      Financial Year 2022
      from bse
- 
    
      Financial Year 2021
      from bse
- 
    
      Financial Year 2020
      from bse
- 
    
      Financial Year 2019
      from bse
- 
    
      Financial Year 2018
      from bse
- 
    
      Financial Year 2017
      from bse
- 
    
      Financial Year 2016
      from bse
- 
    
      Financial Year 2015
      from bse
- 
    
      Financial Year 2014
      from bse
- 
    
      Financial Year 2013
      from bse
- 
    
      Financial Year 2012
      from bse
- 
    
      Financial Year 2011
      from bse
Business Overview:[1]
VBL's core areas include research and development, manufacturing, and distribution of a wide range of pharmaceutical products